Skip to content

US · INSP · MEDICAL - DEVICES

Inspire Medical Systems, Inc. (INSP) intrinsic value and stock valuation

$55.10as of 2026-11-21 · Mkt cap 1.73B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Inspire Medical Systems, Inc. DCF and intrinsic value

InvestorsCraft values INSP with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from INSP’s statements →

Inspire Medical Systems, Inc. Graham Number

Graham Number: $54.44d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Golden Valley, MN 55416 inspiresleep.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$912M+51.2% 5y CAGRd
20152025
Net income
$145.4M
20152025
Free cash flow
$78.5M
20152025
Total equity
$781.2M+27.7% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$912M$802.8M$624.8M$407.9M$233.4M
Operating income$51M$36.1M-$-40.27M-$-47.59M-$-39.85M
Net income$145.4M$53.5M-$-21.15M-$-44.88M-$-42.04M
EPSd$4.89M$1.75M-$-721.84K-$-1.6M-$-1.54M
Operating cash flow$117M$130.3M$24.7M$11.6M-$-20.12M
Capital expenditure-$-38.5M-$-39.12M-$-23.63M-$-9.1M-$-4.67M
Free cash flow$78.5M$91.1M$1.02M$2.47M-$-24.79M
Total assets$918.5M$808.4M$676.8M$564.9M$295.1M
Total debt$32.2M$31.8M$24.9M$16.4M$34.1M
Net debt-$-72.66M-$-118.36M-$-160.69M-$-425.18M-$-180.37M
Total equity$781.2M$689.7M$572.5M$496M$229.1M
Cash and short-term investments$308.3M$445.6M$460.4M$451.4M$214.5M
Income statement
20252024202320222021
Revenue$912M$802.8M$624.8M$407.9M$233.4M
Cost of revenue$133.2M$123M$96.6M$66.1M$33.3M
Gross profit$778.8M$679.8M$528.2M$341.7M$200.1M
Research and development expenses$103.2M$114.1M$116.5M$68.6M$37.4M
Selling, general and administrative expenses$624.6M$529.6M$452M$320.7M$202.6M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$727.8M$643.7M$568.5M$389.3M$240M
Cost and expenses$861M$766.7M$665.1M$455.5M$273.2M
Interest income$17.5M$23.3M$20.6M$5.05M$120K
Interest expense$140K$20K$0.00$1.68M$2.13M
Depreciation and amortization$14M$6.55M$2.85M$1.86M$1.22M
Ebitda$79.8M$65M-$-17.06M-$-40.73M-$-38.62M
Operating income$51M$36.1M-$-40.27M-$-47.59M-$-39.85M
Total other income/expenses, net$14.7M$22.4M$20.4M$3.32M-$-2.12M
Income before tax$65.7M$58.5M-$-19.91M-$-44.27M-$-41.97M
Income tax expense-$-79.72M$4.94M$1.25M$610K$70K
Net income$145.4M$53.5M-$-21.15M-$-44.88M-$-42.04M
Weighted average shares outstanding$29.4M$29.8M$29.3M$28.1M$27.3M
Weighted average diluted shares outstanding$29.8M$30.5M$29.3M$28.1M$27.3M
Balance sheet
20252024202320222021
Cash and short-term investments$308.3M$445.6M$460.4M$451.4M$214.5M
Net receivables$119.7M$93.1M$89.9M$61.2M$34.2M
Inventory$145.3M$80.1M$33.9M$11.9M$17.2M
Total current assets$583.7M$630.8M$593.7M$530M$268.5M
Property, plant and equipment, net$121.4M$95.2M$62.7M$24.1M$16.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$96.3M$71M$9.14M$10.5M$9.94M
Total non-current assets$334.8M$177.6M$83.1M$34.8M$26.6M
Total assets$918.5M$808.4M$676.8M$564.9M$295.1M
Accounts payable$36.6M$38.7M$38.8M$26.9M$11.7M
Short-term debt$2.16M$1.75M$0.00$1.34M$9.5M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$96.1M$88.5M$78.1M$61.2M$41.3M
Long-term debt$30M$30M$24.9M$15.1M$24.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30.1M$30.2M$26.2M$7.68M$24.7M
Capital lease obligations$32.2M$31.8M$24.9M$8.87M$9.11M
Total liabilities$126.2M$118.7M$104.3M$68.9M$66M
Common stock$30K$30K$30K$30K$30K
Retained earnings-$-146.49M-$-291.91M-$-345.42M-$-324.27M-$-279.39M
Accumulated other comprehensive income (loss)$460K$540K$800K-$-90K-$-60K
Total equity$781.2M$689.7M$572.5M$496M$229.1M
Total investments$299.8M$366.4M$284M$20.3M$9.94M
Total debt$32.2M$31.8M$24.9M$16.4M$34.1M
Net debt-$-72.66M-$-118.36M-$-160.69M-$-425.18M-$-180.37M
Cash flow statement
20252024202320222021
Net income$145.4M$53.5M-$-21.15M-$-44.88M-$-42.04M
Depreciation and amortization$14M$6.55M$2.85M$1.86M$1.22M
Stock-based compensation$130.3M$116M$82.5M$52M$26.2M
Change in working capital-$-87.38M-$-37.71M-$-40.78M$1.81M-$-6.86M
Accounts receivable-$-26.23M-$-2.6M-$-30.22M-$-27.02M-$-9.24M
Inventory-$-65.17M-$-46.23M-$-22M$5.34M-$-8.75M
Accounts payable-$-3.75M$600K$9.3M$14.4M$4.78M
Net cash provided by operating activities$117M$130.3M$24.7M$11.6M-$-20.12M
Investments in property, plant and equipment-$-38.5M-$-39.12M-$-23.63M-$-9.1M-$-4.67M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$21.5M-$-113.12M-$-294.82M-$-19.6M$29.1M
Common stock issued$14.6M$27.8M$31.1M$259.6M$15M
Common stock repurchased-$-175.02M-$-75M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-183.45M-$-52.39M$14M$235.1M$15M
Net change in cash-$-45.34M-$-35.39M-$-256.06M$227.1M$24M
Cash at end of period$104.8M$150.2M$185.5M$441.6M$214.5M
Operating cash flow$117M$130.3M$24.7M$11.6M-$-20.12M
Capital expenditure-$-38.5M-$-39.12M-$-23.63M-$-9.1M-$-4.67M
Free cash flow$78.5M$91.1M$1.02M$2.47M-$-24.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Inspire Medical Systems, Inc.

        Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.

        CEO
        Timothy Herbert
        Employees
        1.33K
        Beta
        0.71

        Explore

        Frequently asked questions

        What is the intrinsic value of Inspire Medical Systems, Inc. (INSP)?

        Inspire Medical Systems, Inc. (INSP) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INSP undervalued?

        INSP trades at a price of $55.10 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.